Q2 EPS Estimates for MiMedx Group Lowered by Analyst

MiMedx Group, Inc (NASDAQ:MDXG) – Research analysts at Northland Securities decreased their Q2 2026 earnings per share estimates for shares of MiMedx Group in a research note issued on Thursday, February 26th. Northland Securities analyst C. Byrnes now forecasts that the company will earn $0.01 per share for the quarter, down from their previous estimate of $0.03. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share. Northland Securities also issued estimates for MiMedx Group’s FY2027 earnings at $0.15 EPS.

MDXG has been the subject of a number of other reports. Citigroup initiated coverage on MiMedx Group in a research report on Monday. They issued a “market outperform” rating for the company. Citizens Jmp began coverage on MiMedx Group in a report on Monday. They set a “market outperform” rating and a $10.00 price objective for the company. Mizuho dropped their price target on MiMedx Group from $12.00 to $10.00 and set an “outperform” rating for the company in a report on Wednesday, December 17th. Lake Street Capital decreased their price objective on MiMedx Group from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, January 20th. Finally, Cantor Fitzgerald reduced their target price on shares of MiMedx Group from $12.00 to $8.00 and set an “overweight” rating for the company in a research report on Tuesday, February 17th. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $9.60.

MiMedx Group Stock Down 6.4%

Shares of MDXG stock opened at $4.94 on Friday. MiMedx Group has a 52-week low of $4.80 and a 52-week high of $8.46. The stock has a market cap of $731.61 million, a price-to-earnings ratio of 15.44 and a beta of 1.59. The firm’s 50-day moving average is $5.74 and its 200-day moving average is $6.59. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.95 and a current ratio of 4.41.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings results on Wednesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.05. MiMedx Group had a net margin of 11.60% and a return on equity of 30.61%. The firm had revenue of $118.10 million for the quarter, compared to analyst estimates of $106.78 million.

Institutional Trading of MiMedx Group

Institutional investors and hedge funds have recently made changes to their positions in the company. Divisadero Street Capital Management LP boosted its stake in shares of MiMedx Group by 362.9% in the 2nd quarter. Divisadero Street Capital Management LP now owns 223,220 shares of the company’s stock valued at $1,364,000 after purchasing an additional 175,000 shares in the last quarter. Hussman Strategic Advisors Inc. acquired a new position in MiMedx Group during the 3rd quarter worth approximately $1,759,000. Trigran Investments Inc. lifted its stake in MiMedx Group by 10.4% in the 2nd quarter. Trigran Investments Inc. now owns 8,390,458 shares of the company’s stock valued at $51,266,000 after purchasing an additional 790,901 shares during the last quarter. SG Americas Securities LLC boosted its position in MiMedx Group by 419.3% in the third quarter. SG Americas Securities LLC now owns 161,960 shares of the company’s stock valued at $1,130,000 after buying an additional 130,769 shares in the last quarter. Finally, Integrated Quantitative Investments LLC bought a new stake in shares of MiMedx Group during the second quarter worth $305,000. Institutional investors own 79.15% of the company’s stock.

MiMedx Group News Roundup

Here are the key news stories impacting MiMedx Group this week:

• Positive Sentiment: Q4 beats — MiMedx reported Q4 EPS of $0.14 (vs. $0.09 consensus) and revenue of ~$118.1M (vs. ~$106.8M consensus), showing healthy top‑ and bottom‑line beats and margin expansion. MiMedx Q4 Earnings and Revenues Beat Estimates
• Positive Sentiment: Record results and capital return — The company called Q4 and full‑year 2025 results “record,” reported $29M adjusted EBITDA for the quarter, and announced a $100M share repurchase authorization, which supports shareholder value. GlobeNewswire Press Release
• Neutral Sentiment: Earnings call available — Management discussed surgical growth initiatives and reimbursement dynamics on the call; investors can listen to the transcript for detail on execution plans and timing. MiMedx Q4 2025 Earnings Call Transcript
• Neutral Sentiment: New analyst coverage started — Citizens JMP began coverage (coverage initiation may add visibility but its rating/price target will determine impact). Citizens JMP Begins Coverage
• Negative Sentiment: Guidance below consensus and reimbursement uncertainty — Management guided FY‑2026 revenue to $340M–$360M, below the ~ $375M street estimate, and highlighted navigating reimbursement changes; the guidance shortfall and policy uncertainty are the primary bearish catalysts. MiMedx targets $340M–$360M 2026 revenue
• Negative Sentiment: Market reaction — Heavy intraday volume and the stock trading near its 52‑week low suggest investors are selling into the guidance/uncertainty despite the quarter’s beats and buyback announcement. Company Press Release / Financials

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.